A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression.

  title={A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression.},
  author={Jeffrey T. Kuvin and Maria E. R{\"a}met and Ayan R. Patel and Natesa G. Pandian and Michael E. Mendelsohn and Richard H Karas},
  journal={American heart journal},
  volume={144 1},
BACKGROUND Low levels of high-density lipoprotein (HDL) cholesterol increase the risk of coronary artery disease (CAD), and recent clinical studies suggest that interventions in low-HDL patients are beneficial. The purpose of this study was to examine the effect of increased HDL levels on endothelium-dependent vasodilation. METHODS We studied patients with CAD with a low-density lipoprotein (LDL) level of <100 mg/dL. Patients with an HDL level of < or =36 mg/dL were treated with niacin (n… 

Figures and Tables from this paper

High-Density Lipoprotein Cholesterol and Coronary Heart Disease

The role of HDL in coronary heart disease is highlighted, from basic mechanisms of action to recent clinical trial results, and several therapeutic interventions can augment HDL concentrations, and there is increasing evidence that these interventions improve cardiovascular outcomes.

Effects of high-density lipoprotein on endothelium-dependent vasorelaxation.

This study demonstrates that both ApoA-I and SR-BI associate with eNOS in the vascular wall and does not result in modulation of either NO formation or endothelial function.

Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease

It will be important to determine, which biological functions of HDL are critical for its anti‐atherosclerotic properties, as well as how these can be measured and targeted.

High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease1

Different effects of HDL on endothelial cell functions potentially relevant to atherosclerotic vascular disease are addressed and molecular mechanisms leading to “dysfunctional HDL” are explored.

High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.

Reduced levels of high-density lipoprotein cholesterol (HDL) are associated with a substantially increased risk of coronary disease and cardiovascular events. Furthermore, numerous studies have

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.

Fenofibrate therapy significantly improved percent flow-mediated dilator response to hyperemia, reduced inflammation marker levels, increased adiponectin levels, and improved insulin sensitivity in hypertriglyceridemic or metabolic syndrome patients.



The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.

The improvement in endothelium-dependent vasomotion with cholesterol-lowering and antioxidant therapy may have important implications for the activity of myocardial ischemia and may explain in part the reduced incidence of adverse coronary events that is known to result from cholesterol- Lowering therapy.

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.

Although the predominant lipid-modifying effect of fluvastatin is to decrease LDL-C, patients with low HDL-C received the greatest angiographic and clinical benefit; among low-HDL-C patients, fluVastatin patients had improved event-free survival compared with placebo patients.

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.

It is suggested that cholesterol-lowering therapy with pravastatin may improve endothelium-dependent coronary vasomotion, which may possibly contribute to the improvement of myocardial perfusion as well as the regression of coronary atherosclerosis.


Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level, suggesting that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.

Cholesterol lowering with lovastatin significantly improved endothelium-mediated responses in the coronary arteries of patients with atherosclerosis, and improvement in the local regulation of coronary arterial tone could potentially relieve ischemic symptoms and signal the stabilization of the atherosclerotic plaque.

Aspirin improves endothelial dysfunction in atherosclerosis.

Cyclooxygenase-dependent, endothelium-derived vasoconstrictor release modulates acetylcholine-induced peripheral vasodilation in patients with atherosclerosis and provides a pathophysiological basis for the beneficial effects of aspirin in Atherosclerosis.

High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules.

Physiological concentrations of HDLs inhibit tumor necrosis factor-alpha or interleukin-1 (IL-1) induction of these leukocyte adhesion molecules in a concentration-dependent manner and have no effect on TNF-alpha-induced expression of ICAM-1 by human foreskin fibroblasts, suggesting that the effect is cell-type restricted.